Posted by AGORACOM-JC
at 9:44 AM on Tuesday, April 6th, 2021
Announced that it has acquired 2,223,215 Syscoin tokens which it intends to hold as a long term asset.
The Company purchased these Syscoin tokens for approximately C$0.45 per token for a total of CAD$1 million.
This investment brings BCF’s total Syscoin treasury holdings to approximately 6,353,607 Syscoin, worth approximately CAD$3 million at current market rates 1 .
The Company “stakes” its current Syscoin balances and intends to stake its additional Syscoin holdings.
Staking currently generates an annual return of approximately 5.71% 2 , increasing to approximately 7.71% after tokens have been staked for one year.
TORONTO, April 06, 2021 — Blockchain Foundry Inc. (“BCF” or the “Company”) (CSE:BCFN), a leading North American blockchain development firm, is pleased to announce that it has acquired 2,223,215 Syscoin tokens which it intends to hold as a long term asset. The Company purchased these Syscoin tokens for approximately C$0.45 per token for a total of CAD$1 million. This investment brings BCF’s total Syscoin treasury holdings to approximately 6,353,607 Syscoin, worth approximately CAD$3 million at current market rates 1 . The Company “stakes” its current Syscoin balances and intends to stake its additional Syscoin holdings. Staking currently generates an annual return of approximately 5.71% 2 , increasing to approximately 7.71% after tokens have been staked for one year.
BCF believes strongly in the future of Syscoin, its growing market acceptance as a blockchain infrastructure ecosystem, and its future valuation potential. The Company is a core contributor to the open source Syscoin protocol and has also created proprietary applications that rely on the Syscoin ecosystem. Going forward, BCF intends to create decentralized finance applications, including NFT systems, using Syscoin’s infrastructure.
On April 30, 2021 3 , the Syscoin protocol will have its first upgrade since December 2019, upgrading to Version 4.2, known as Syscoin LUX (“LUX”). LUX will introduce several cutting-edge features into Syscoin, including zero-fee layer 2 smart contract functionality, fractional and non-divisible NFT capabilities and notary features which allow for customizable payment rules defined off-chain to be enforced at the core blockchain level. LUX will also preserve Z-DAG, Syscoin’s patent pending high-throughput transaction technology which allows for more than 140,000 transactions per second at scale.
“We are pleased to be making a substantial financial investment in Syscoin as we look forward to the upcoming release of Syscoin LUX. Creating strong economic alignment between the Company’s Syscoin-related efforts and the potential appreciation of the Syscoin token is important so that BCF shareholders can directly benefit from increasing adoption and acceptance of the Syscoin token and infrastructure as enabled by BCF products and open source contributions,” said Dan Wasyluk, CEO of BCF.
Commenting further, Mr. Wasyluk added, “our enterprise software and decentralized finance product strategies rely on using Syscoin blockchain infrastructure for our product offerings, and investing financially in the success of the ecosystem allows our shareholders to directly benefit from this growth. The innovative features BCF has contributed to LUX are a direct response to the needs of our clients and cover a wide variety of use cases. These new features will serve as the backbone for certain BCF products. Additionally, LUX will enable developers to create applications powered by Syscoin Platform Tokens using the same languages and tools with which they’re already familiar.”
LUX enhances the core offering of Syscoin as a scalable, versatile and innovative blockchain platform and for the first time includes major new features sourced directly from BCF’s consulting practice, a real-world touch point unique to BCF’s strategy. The Company expects that LUX and the related products and use cases it supports will further enhance BCF’s reputation as a leading blockchain technology company and contribute further to BCF’s growth and the overall growth and acceptance of the Syscoin ecosystem.
Posted by AGORACOM
at 9:30 AM on Tuesday, April 6th, 2021
Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021
MONTRÉAL, April 6, 2021 – Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTC: ORTIF) (” Ortho RTI ” or the ” Company “), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase I/II clinical trial of ORTHO-R in rotator cuff tear repair.
“The IND submission for our first ORTHO-R human trial is a key milestone for the Company. It brings us one step closer to the enrollment of our first patient, a recognized value creation event in our industry”, said Claude LeDuc , President and CEO of Ortho RTI.
“There is a clear need for improved rotator cuff tear repair treatments, as estimates have put the re-tear (or non healing) rate at an average of 50%. With more than 600,000 patients undergoing rotator cuff surgery every year in the U.S., this represents an enormous commercial opportunity, and as demonstrated in 2020 by our GLP preclinical program results, we strongly believe that ORTHO-R can help address these significant unmet needs and meaningfully improve the success rate of these surgeries.”
Posted by AGORACOM
at 9:26 AM on Tuesday, April 6th, 2021
– A realtime, actionable solution using Health Gauge’s AI-powered wearables –
TORONTO, ON / April 6, 2021 / AI/ML Innovations Inc. (CSE:AIML), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that its subsidiary, Health Gauge, has developed a strategic partnership with My Viva Plan (“MVP”) designed to effectively leverage the two companies’ collective strengths and core assets, in order to best serve digital wellness market interests at the enterprise level.
Collectively, Health Gauge and MVP have created and implemented a strategy to address Metabolic Rehabilitation, with a comprehensive program that helps patients with certain chronic illnesses to understand and harness risk factors such as obesity, high blood glucose levels, high blood pressure, and more, thus mitigating the risk of diabetes, heart disease and stroke.
“Following the launch of Health Gauge’s comprehensive wearable solution, AIML is positioning to participate in the US$58 billion wearables market in a significant way,” said Tim Daniels, Executive Chairman of AI/ML Innovations Inc.
“Additionally, the digital therapeutics market for the rehabilitation of Metabolic Disorder is growing rapidly. Health Gauge’s AI-driven digital health monitoring solution, in tandem with MVP’s individualized care plans and personal health assessments, which is supported by professional care providers and dieticians, is a uniquely powerful combination poised to disrupt this industry.”
Posted by AGORACOM
at 9:25 AM on Tuesday, April 6th, 2021
NAM has contracted EarthEx Geophysical Solutions (EarthEx) to conduct several UAV-Borne Magnetometry Surveys on the Company’s Lithium Projects in southeast (SE) Manitoba
The program is being co-funded by the Company and the Manitoba Mineral Development Fund (MMDF) which is administered by the Chamber of Commerce
NAM has 100% ownership of seven pegmatite hosted Lithium and Rare Element Projects in the Winnipeg River Pegmatite Field, located in SE Manitoba
NAM’s exploration focus on SE Manitoba is on Lithium-bearing pegmatites – The seven projects are strategically situated within the Winnipeg River Pegmatite Field
New Age Metals Inc. (NAM) (TSXV:NAM); (OTC:NMTLF); (FSE:P7J) (“NAM” or the “Company”) is pleased to announce that a Drone Magnetic Survey is being initiated on their Lithium Projects in SE Manitoba through their wholly owned subsidiary, Lithium Canada Development.
The Drone Magnetic Survey is a UAV-Borne Magnetometry survey. The present system being used by EarthEx is the highest resolution drone magnetics system on the market today. EarthEx is a Manitoba-based geophysical consulting company. Daniel Card, Chief Geophysicist and President of EarthEx said “We are excited to be working with such a highly reputable company as New Age Metals, in this prolific pegmatite district, providing services which will accelerate the path to new discoveries.” The EarthEx airborne magnetic geophysical survey technology will be used to further define future drill targets for the Company’s Lithium Two, Lithman West and Cat Lake Lithium Projects, Figure 1.
Harry Barr, Chairman and CEO stated, “Our team is busy advancing the Lithium Projects in SE Manitoba. Drilling is occurring in the next few weeks on one of our Lithium Projects and the Drone Magnetic Survey will help us better determine other drill targets. The potential for economic Lithium Deposits in Manitoba is strong and New Age with its Lithium Division, Lithium Canada Development are pleased to be fully funded and active in the Lithium space in Manitoba. We are also very fortunate to be partnering with the Manitoba Mineral Development Fund again on this work program to help develop this underexplored lithium region.”
Posted by AGORACOM-JC
at 8:49 AM on Tuesday, April 6th, 2021
Announced the launch of its new YouTube series entitled “Taste This!” as the Company further expands its offering of content aimed at educating consumers on plant-based living.
The series will be produced and hosted by Mr. Adam Kruger .
Each episode of Taste This! will feature three different brands of the same food product which are then blind taste-tested by three individuals.
The taste-testers will then give their opinions about the products that they tasted, which product they preferred and attempt to identify the brand.
VANCOUVER, BC , April 6, 2021 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce the launch of its new YouTube series entitled “Taste This!” as the Company further expands its offering of content aimed at educating consumers on plant-based living. The series will be produced and hosted by Mr. Adam Kruger . Each episode of Taste This! will feature three different brands of the same food product which are then blind taste-tested by three individuals. The taste-testers will then give their opinions about the products that they tasted, which product they preferred and attempt to identify the brand.
“Having a media presence further establishes the PlantX brand while aiding customers in their decision-making process for what to purchase online. Looking at pictures and reading ingredients is great, but being able to actually see people taste and compare different products creates excitement around the products involved,” said PlantX CEO Julia Frank . “We believe media content will increase enthusiasm for the brands being featured on the program.”
“We are so excited to launch this series. Customer education is one of our priorities, and Taste This! is exactly the quality content that will contribute to that,” said PlantX Founder Sean Dollinger . “Adam’s experience and plant-based lifestyle only enhance the production and we are thrilled to have him producing the show.”
Kruger is an on-camera and live event host, producer, podcaster and longtime vegan. Kruger hosted and produced over 150 segments for the hit lifestyle series ” This Is LA “. Most recently, he launched the podcast “Enhanced Living” which is available on major streaming platforms.
“Adam is a true professional and having him at the helm of the series brings peace of mind,” said PlantX CMO Alex Hoffman. “After conceiving this idea, I knew exactly what I wanted to create for the series. Adam brought it to life, and I can’t wait to see more.”
The series teaser can be found here . The first episode of ” Taste This! ” will air on Friday, April 9 th 2021 at 6pm PST .
About PlantX Life Inc.
As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.
About Adam Kruger
Adam Kruger is a longtime vegan with over 20 years’ experience in the entertainment industry. Originally from Montréal, Adam moved to Los Angeles after completing his Bachelor of Commerce degree from the John Molson School of Business at Concordia University . Kruger has achieved success in television hosting and standup comedy, while also running a live event business of his own since 2013. Kruger has been a keynote speaker in front of thousands of people, is an avid fitness enthusiast and also completed a 200 hour comprehensive yoga and Ayurveda instructor training. Krueger has been on a plant-based diet since 2009 and became a vegan in 2016.
Posted by AGORACOM
at 8:47 AM on Tuesday, April 6th, 2021
Royal Helium Ltd. (“Royal” or the “Company”) (TSXV: RHC) is pleased to announce that initial gas sample test results have returned elevated and economic levels of helium concentration from multiple formations at the Climax helium project, with tests returning levels ranging from 0.33% to 0.94% from the Deadwood, Souris River and Duperow formations. The company will now commence long term production testing of the most prospective zones to confirm flow rates and ultimately resource size.
The high graded production zones that are being tested range in thickness from five meters to in excess of 30 meters, with the ability to expand to even larger intersections. While these results are preliminary in nature and require additional confirmation, they do confirm the presence of economic helium grades on the Climax project, along with indicating that nitrogen will be the primary gas drive, though elevated levels of carbon dioxide are also present in certain tests. To date, testing has been focused on testing helium concentrations across the prospective zones with the highest level of helium detected during the drilling process. This initial concentration testing at Climax is expected to be completed over the next 10 days, following which the Royal will begin full flow testing and analysis which is expected to take an additional 30- 40 days.
Andrew Davidson, President and CEO of Royal comments “We are pleased with these initial results on our Climax helium project. Helium detection during drilling identified multiple zones of elevated helium in all three of the wells and follow-up completions testing confirmed economic helium concentrations. We look forward to the full flow testing results across all zones of interest in each of the three wells to confirm resource size and project commerciality. The fact that we have identified elevated and economic helium concentrations across significant pay zones as large as 30 meters speaks to the potential of the Climax Project.”
Posted by AGORACOM-JC
at 8:46 AM on Tuesday, April 6th, 2021
Amended license with AerialX Drone Solutions Inc. provides for exclusive rights to U.S. and Canadian militaries
Announced that it has signed an Amended and Restated License Agreement with AerialX Drone Solutions Inc. for counter-drone technology. I
n October 2019 KWESST signed a non-exclusive worldwide license with AerialX and has now gained exclusive rights to the technology for U.S. and Canadian militaries.
The product which is based on the licensed technology is being marketed under the name GreyGhostTM and is an autonomous soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact.
Ottawa, Ontario–(April 6, 2021) – KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) (“KWESST” or “the Company”) today announced that it has signed an Amended and Restated License Agreement (the “Agreement”) with AerialX Drone Solutions Inc. (“AerialX”) for counter-drone technology. In October 2019 KWESST signed a non-exclusive worldwide license with AerialX and has now gained exclusive rights to the technology for U.S. and Canadian militaries. The product which is based on the licensed technology is being marketed under the name GreyGhostTM and is an autonomous soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact.
The dramatic growth of small unmanned aircraft systems (sUAS), commonly called drones, creates new threats and challenges for NATO countries including the US Department of Defense (DoD) and Canada’s Department of National Defence (DND). Recent technology trends have enabled state actors, non-state actors, terrorist organizations and criminals to easily convert legitimate applications of sUAS into efficient weapons. These small drones provide NATO adversaries with a low-cost means of conducting intelligence, surveillance, and reconnaissance missions or direct attack of NATO forces.
“This is a timely development as the U.S. and other NATO military agencies have expressed interest in our GreyGhostTM counter-sUAS drone missile and view it as a serious candidate solution to the growing threat of suspicious or hostile drones,” said David Luxton, KWESST’s Executive Chairman. “Our GreyGhostTM counter-sUAS drone missile has been down-selected by key agencies from among dozens of contenders for upcoming demonstrations and trials because of its unique ability to track and hunt hostile drones and neutralize them with kinetic impact.”
“The Pentagon last year established the Army-led Joint Counter-Small Unmanned Aircraft Systems Office, or JCO, and approved a set of requirements to help counter the threat posed by small drones and formalized requirements for how technology developed by industry players can seamlessly plug into a single command-and-control system. Evaluation of industry counter drone systems are expected to be ongoing throughout 2021,” said Jeff MacLeod, KWESST’s President and CEO. “In the U.S. and in 2021 alone, DoD plans to spend at least USD $404 million on counter-UAS (c-UAS) research and development and at least $83 million on c-UAS procurement(1).”
The counter drone market has grown considerably in recent years, with both major defense contractors and small technology companies actively competing to gain market share in a market that by one estimate could be worth $5.4 billion by 2028(2).
Under the Agreement announced today, KWESST’s also retains its non-exclusive worldwide rights. KWESST has agreed to issue AerialX 100,000 shares of KWESST in consideration of the new exclusive rights and an additional 100,000 shares of KWESST upon AerialX meeting certain technological milestones.
Posted by AGORACOM-JC
at 8:21 AM on Tuesday, April 6th, 2021
Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, will be presenting at Zooming with LD on Monday April 12 th , 2021.
MONTREAL, April 06, 2021 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), (the “Company”, the “Corporation” or “PyroGenesis”) a Company that designs, develops, manufactures and commercializes plasma atomized metal powder, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, is pleased to announce that, Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, will be presenting at Zooming with LD on Monday April 12 th , 2021.
LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.
In September 2020, LD Micro was acquired by SRAX, a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.
About PyroGenesis Canada Inc.
PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m 2 and 2,940 m 2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com .
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or atwww.sec.gov.Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as requiredby applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the NASDAQ Stock Market, LLC accepts responsibility for the adequacy or accuracy of this press release.
SOURCE PyroGenesis Canada Inc.
For further information please contact: Rodayna Kafal, Vice President, IR/Comms. and Strategic BD Phone: (514) 937-0002, E-mail: [email protected]
Posted by AGORACOM-JC
at 8:12 AM on Tuesday, April 6th, 2021
Completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.
MONTREAL , April 6, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.
“The successful conclusion of negotiations with pCPA is a significant milestone delivered for the Redesca® commercialization program. We can now exchange with the provincial, territories and federal instances to ensure coverage under publicly funded drug plans in Canada “, said Steve Saviuk , Valeo’s CEO.” While most prescriptions of LMWHs are initiated in the hospital, retail pharmacies play an important role in providing continued treatment to patients when they are discharged from hospital. Coverage by publicly funded drug plans are therefor a key component in making treatment available to Canadians”.
Commenting on the pCPA LOI, Frederic Fasano , Valeo’s President and Chief Operating Officer said; “We are particularly pleased to make Redesca ® available soon for Canadian patients and also for hospitals. The team at Valeo have worked tirelessly to ensure a robust supply of Redesca ® especially in the current pandemic conditions where patients suffering from SARS-CoV-2 are undergoing severe coagulopathy with various thromboembolic complications. LMWHs, like Redesca ® are key to prevent and treat those severe COVID-19 related thrombotic events.”
Established in August 2010 , the pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial/federal negotiations for brand name and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients through the use of the combined negotiating power of participating jurisdictions.
About Redesca®, Redesca HP®
Redesca® is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca® has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
